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Abstract
Objective To evaluate the efficacy, adverse effects, and
recurrence of oral propranolol for treatment of infantile
hemangioma.
Methods Participants were treated with oral propranolol
three times daily, with inpatient monitoring of adverse
effects. The starting dosage was 2 mg/kg per day, which
had been for the remaining duration of treatment. Therapy
duration was planned for 4–6 months; if there was signif-
icant relapse, the period of treatment was extended. A
photograph based severity scoring assessment was per-
formed by three observers to evaluate efficacy by visual
analog scale (VAS).
Results Sixty-one infants [median age 3.3 (1.2–8.1)
months] were included in the study. The median follow-
up-time was 15 (6–20) months and 53 patients completed
treatment at a median age of 10.3 (8.4–18.1) months, after
a duration of 8.5 (4.5–14) months. In all patients, there was
significant fading of color [with a VAS of -9 (-6 to -9)
after 6 months] and significant decrease in size of the
infantile hemangiomas [with a VAS of -8 (-3 to -10)
after 6 months]. We did not observe any life-threatening
adverse effects. The therapy was interrupted due to tem-
porary aggravation of pre-existing bronchial asthma in one
child. Four cases presented partial recurrences.
Conclusions Oral propranolol 2 mg/kg per day was a
well-tolerated and effective treatment, mild adverse effects,
and low recurrence for infantile hemangiomas. Propranolol
should now be used as a first-line treatment in hemangio-
mas when intervention is required. Also, prospective
studies should be needed in determining the most effective
treatment dosage, optimum treatment duration, and exact
mechanism of action of propranolol in future.
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Introduction
Infantile hemangiomas (IHs) are benign vascular tumors
found in approximately 5–10 % of all newborns and infants
up to 1 year. Although most do not need treatment due to
their self-limited, approximately 10 % require medical
intervention, include those involving the periorbital area,
central face, airway, skin folds, anogenital area, sites at
high risk for ulceration, dysfunction, or disfigurement.
Systemic corticosteroids have been the mainstay of treat-
ment for more severe IH; however, the response is variable,
and side-effects are insidious and difficult to monitor.
Moreover, corticosteroids work best at stopping further
growth, but actual shrinkage only occurs in approximately
one-third of patients [1]. Other treatment options for
problematic IH include intra-lesional corticosteroids, vin-
cristine, interferonalpha, cyclophosphamide, laser, surgery,
or a combination of these therapies. However, each of these
modalities has limited therapeutic benefit with its own side-
effect profile and potential serious risks [2, 16].
Le´aute´-Labre`ze et al. [3] reported the incidental finding
that hemangiomas regress in children treated with
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propranolol, a non-selective beta-blocker used in treating
infants with cardiac and renal conditions. This report has
been met with great interest and enthusiasm and physicians
all over the world have started to use propranolol for the
treatment of problematic IH. Although a definite reduction
or even disappearance of IH is well-documented with
propranolol, the experience of many authors indicates that
a number of IH recur after propranolol withdrawal, as has
been stated in several articles, although the rate and the
possible causes of recurrence have not been established [4–
9]. The small number of cases treated worldwide, the lack
of long-term protocols, the heterogeneity in the behavior of
IH, and the short period of time that propranolol has been
used for the treatment of IH make it difficult to assess main
data associated with IH recurrence after therapy with-
drawal [10–14].
In the present study, we report one of the largest case
series to date, that of 64 infants treated with propranolol,
including efficacy, side effects, and recurrence.
Patients and methods
Propranolol was administered to 64 children with IH
associated with life-threatening potential, functional risk,
local complications, or cosmetic disfigurement. A treat-
ment guideline was designed that was based on the known
side effects of propranolol and in collaboration with pedi-
atric cardiologists, hematologists, dermatologists, and
plastic surgeons. After initial evaluation and informed
consent and explanation of alternative therapeutic options,
patients were scheduled for 3-day inpatient hospitalization.
Before treatment was started, an electrocardiogram was
performed to detect any pre-existing cardiac conduction
disturbance. Serial photographs of the IH were obtained to
evaluate the efficacy of propranolol. The dosage was 2 mg/
kg per day. Parents were instructed to interrupt the
administration of the drug if the child had a serious cough
with dyspnea. Follow-up visits were scheduled monthly
and at any time in case of complications. The dosage of
propranolol was adjusted to the weight of the patient only
in case of relapse of the hemangioma or a stop in regression
after an initially observed decrease. At each clinic visit,
blood pressure, heart rate, and blood glucose was mea-
sured, the effect of the treatment were determined, and
possible adverse events were documented. We obtained
serial clinical images to assess the rate and degree of
recurrence. A visual scale to assess the severity of the IH
was used. Briefly, three of the authors independently
evaluated clinical images taken at baseline and in the fol-
low-up visits. The observer documented changes in color
and size of the lesions on a visual analog scale (VAS)
ranging from -10 to ?10 by comparing follow-up images
to the baseline photograph pre treatment. On the VAS 0
represented the baseline photograph (pre-treatment), a
decrease in color or size resulted in a - number, an
increase in color or size in a ? number.
Statistical analysis
Data collected from the patients’ charts, ultrasound
examination, and evaluation of photographs by VAS were
entered into a computerized database. Median and range
were calculated for continuos values. The Wilcoxon test
was used to compare two related samples and the null
hypothesis was rejected with a two-sided p value of\0.05.
Results
Sixty-four patients with IH were included in the study. The
relevant epidemiologic and clinical characteristics of the
patients and details about the individual treatment indica-
tion and duration are shown in Table 1. The female-to-
male ratio was 3.9:1. The median age at start of treatment
with propranolol was 3.6 (0.5–9.1) months. Three patients
were previously preterm infants born at 36 weeks of ges-
tation and at initiation of treatment they were all older than
40 weeks of gestation. In two infants, laser therapy had
been performed earlier without success and their IH con-
tinued to increase in size. All patients were treated with
propranolol at a dose of 2 mg/kg per day. Fifty-three
patients completed treatment at median age of 10.3
(8.4–18.1) months and after a median treatment duration of
8.5 (4.5–14) months. Eleven patients had ongoing therapy
with propranolol at the time of writing this paper (Table 1).
The median follow-up-time of all patients was 15 (6–20)
months. Treatment response all IH stopped growing faded
in color and became smaller (Figs. 1, 2). VAS measure-
ments of photographic documentation were available at
time points 0 (baseline), 3 days, 1, 2, and 6 months. Fig-
ure 3a, b demonstrates the changes of VAS values for color
and size of the lesions over time. There was significant
fading of color and decrease in size of the IH during the
follow-up period compared to the photographs at baseline.
Of note, the VAS already decreased significantly within the
first 3 days of therapy for both, color and size. After
6 months, fading of color was reached with a VAS of -9
(-6 to -9) and shrinking of the lesions with a VAS of -8
(-3 to -10).
Side effects
No severe adverse events were noted in our patients.
Thirteen (23.6 %) showed a reaction possibly due to the
medication. Therapy was interrupted in one child who had
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temporary aggravation of preexisting asthma. All other
observed adverse effects were mild and were tolerated
without discontinuing the medication (Table 2).
Recurrence
A summary of all cases is presented in Table 3 and Fig. 4.
Discussion
Propranolol was the first clinically useful beta-adrenergic
receptor antagonist. Invented by Sir James W. Black, it
revolutionized the medical management of angina pectoris
and is considered to be one of the most important contri-
butions to clinical medicine and pharmacology of the
twentieth century [15]. Beta-blockers may also be referred
to as beta-adrenergic blocking agents, beta-adrenergic
antagonists, or beta-antagonists. Propranolol is a non-
selective beta-blocker. The levorotatory isomer of pro-
pranolol binds reversibly with b1- and b2-adrenoreceptors;
both receptors have membrane stabilizing activity [16].
Efficacy
The response of infantile hemangiomas to propranolol
reported in the New England Journal of Medicine by
Le´aute´ -Labre`ze et al. [3] catapulted the use of this treat-
ment to first-line status among physicians managing this
disease [17, 18]. Regulators of hemangioma growth and
involution are poorly understood. Infantile hemangiomas
are composed of a complex mixture of clonal endothelial
cells associated with pericytes, dendritic cells, and mast
cells. Hemangiomas usually appear a few weeks after birth
Table 1 Summary of baseline characteristics and treatment of
infantile hemangiomas















Age initiation of propranolol (months) median (range) 3.6
(0.5–9.1)
Duration of propranolol treatment (months), n = 64
median (range)
8.5 (4.5–14)




Duration of propranolol treatment until stopped,
n = 53 median (range)
8.5 (4.5–14)
A pre-treatment B 1 month after treatment
C 3 month after treatment D 12 month after treatment
Fig. 1 a Child present at
2 months of age before
treatment. b Spontaneous
regression after 1 month of
propranolol treatment at
2 mg/kg per day. c Further
improvement after 2 months.
d Residual telangiectases at
12 months of age, after
cessation of propranolol
treatment
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and grow more rapidly than the infant does. This prolif-
erative phase of hemangiomas is characterized histologi-
cally by plump endothelial cells with frequent mitosis, an
increased number of mast cells and multilaminated base-
ment membranes. Two major proangiogenetic factors are
involved: basic fibroblast growth factor (bFGF) and vas-
cular endothelial growth factor (VEGF). This period is
followed by spontaneous slow involution, which shows
apoptosis, and is morphologically characterized by flat,
inactive, and normal-appearing endothelial cells in a matrix
of the so-called ‘‘fibrous-fatty tissue’’ [19, 20]. In all
patients, there was significant fading of color [with a VAS
of -9 (-6 to -9) after 6 months] and significant decrease
in size of the IH [with a VAS of -8 (-3 to -10) after
6 months]. Potential explanations for the therapeutic effect
of propranolol on hemangiomas include vasoconstriction,
which is immediately visible as a change in color, associ-
ated with a palpable tissue softening. Other included sug-
gestions are a down-regulation of angiogenetic factors such
as VEGF and bFGF and an up-regulation of apoptosis of
capillary endothelial cells [3, 21]. There are also data
published which indicate a selective role of propranolol in
inhibiting the expression of MMP-9 (angiogenic and
extracellular matrix degrading enzyme) and HBMEC
(human brain microvascular endothelial cells). These facts
A pre-treatment B 1 month after treatment
C 3 month after treatment D 6 month after treatment
Fig. 2 a Patient was referred
aged 3 months with rapidly
growing hemangioma in left
chest. b After 1 month of
propranolol treatment at
2 mg/kg per day. c After
3 months of propranolol
treatment at 2 mg/kg per day.
d After 6 months of propranolol



































Fig. 3 Changes of VAS
regarding color (a) and size
(b) of the hemangiomas during
follow-up and treatment with
propranolol (BL baseline,
d days, m months); p \ 0.01 for
both parameters
Table 2 Complications and adverse effects
Observed adverse effects n (%) Propranolol terminated





Restless sleep 3 0






Bronchial asthma 1 1
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may potentially add to propranolol’s anti-angiogenetic
properties. HBMEC play an essential role as structural and
functional components in tumor angiogenesis [22].
Adverse effects
We did not observe any severe adverse effects, although
there have been a few reports of serious adverse effects,
particularly hypoglycemia. Adverse effects of beta-block-
ers for other medical indications have also been reported,
including hypotension, bradycardia, bronchospasm, and
hypoglycemia [23, 24]. Non-selective beta-blockers are
competitive antagonists of catecholamines at the b-1 and b-
2 adrenergic receptors. Beta-2 receptor blockade may result
in hypoglycemia as a result of decreased glycogenolysis,
gluconeogenesis, and lipolysis. Lawley et al. [10] reported
the cases of two patients who received propranolol in the
recommended dosage of 2 mg/kg per day. One experienced
severe hypotension and the other severe hypoglycemia.
Other authors have reported similar cases [6, 13, 17]. Burns
et al. [25] stated that hypoglycemia can be associated with
poor neurological outcome. Symptomatic hypoglycemia
can be a serious complication of propranolol treatment. A
propranolol dosage of over 4 mg/kg per day seems to put
the pediatric patient at risk for development of hypogly-
cemic events [26]. Propranolol had to be discontinued in
one patient because of bronchial hyperreactivity during
viral infections. Bronchial hyperreactivity is a direct effect
of non-beta-selectivity of propranolol, resulting in bron-
chospasm due to pulmonic beta-2-blockade. The use of a
non-selective lipophilic beta-blocker results in several
other reported side effects. Restless sleep is probably a
direct result of the lipophilic character of propranolol,
which allows it to cross the blood brain barrier. A solution
to many of the side effects of propranolol therapy may be
the use of more selective b-1 antagonists such as meto-
prolol, which, at low dosage, have little b-2 activity; thus,
in theory they bear a lower risk of inducing hypoglycemia
Table 3 Visual scale scoring as evaluated three independent observers











1 Left temple and
periorbital
10 ± 2 1.7 ± 10 7.43 ± 16 Deep Segmental Yes, good
response




3 Upper lip 9 ± 3 3.54 ± 9 6.32 ± 15 Deep Segmental Yes, good
response
4 Right arm 9 ± 7 0 ± 13 5 ± 21 Deep Focal No
Fig. 4 Clinical images of
patient 1, a before starting
treatment with propranolol; b at
withdrawal; c recurrence at the
age of 14 months; d clinical
images after second treatment
with propranolol
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and bronchospasm. Treatment with a hydrophilic beta-1
antagonist such as atenolol may prevent side effects, such
as restless sleep. However, it is not yet known if these
selective beta-blockers will have efficacy that is equal to
propranolol. Our study confirms the impressive results of
propranolol as a treatment for IH. It seems to be a more
effective and safer therapeutic drug than systemic corti-
costeroids. Its use may be expanded to treatment of IH after
the first year of life. Because of potentially harmful side
effects, including hypoglycemia, bronchospasm, and
hypotension, these patients is preferably treated in a mul-
tidisciplinary setting by physicians knowledgeable about
the effects and side-effects of propranolol.
Recurrence
As has been mentioned in several articles, we confirmed that
IH successfully treated with propranolol may recur
0–6 months after therapy withdrawal. The rate of clinically
visible recurrence of IH in our series of 64 patients was 6 %,
suggesting that four cases propranolol does not result in
permanent shrinkage. The frequency of recurrences in
patients treated with propranolol has not been well-charac-
terized. In the series of cases reported by Sans et al. [9], 2 of
25 patients (8 %) had recurrences after treatment with-
drawal. The overall response to retreatment with propranolol
was satisfactory. These relapses occurred before the age of
11 months, which might mean that the treatment was with-
drawn before the proliferative phase of the IH was over [9].
The cause of relapse in our cases is unknown, and the low
number of patients in our series does not allow for definite
conclusions. Propranolol withdrawal was considered
because the IH had completely stabilized or was almost
completely gone. Clinically overt recurrence may indicate
that the proliferative phase of the IH was still ongoing, as has
been described in hemangiomas with a deep component and
segmental morphologic characteristics [27]. In our experi-
ence, these two features were more frequent in the recurring
group. It is difficult to predict which IH will have a late
proliferative phase. The mean duration of treatment in the
four recurrent IH in our series was longer than in the non-
recurrent cases. Thus, we speculate that it is difficult to
establish fixed periods of treatment for patients with IH, and
the duration of treatment with propranolol must be individ-
ualized according to intrinsic features of the IH or its clinical
evolution, which are largely unpredictable. Although no data
are available regarding recurrence rate after retreatment
withdrawal, in our experience, response to a second treat-
ment with propranolol in the recurrent cases has been satis-
factory. In any case, it should be kept in mind that late
relapses may occur and that patients with IH treated with
propranolol should be followed up for at least 6 months after
stopping this treatment. Hemangioma recurrence is also
often seen in patients treated with corticosteroids. Although a
comparison of the two treatments is not possible, it is the
authors’ impression that the rate of recurrence is lower with
propranolol than with corticosteroids. The main proposed
mechanisms involved in the effectiveness of propranolol for
IH include vasoconstriction, inhibition of angiogenesis,
inhibition of the renin–angiotensin system, and induction of
apoptosis [28, 29]. Apoptosis of endothelial cells in the
hemangioma is supposed to be the most likely mechanism
involved in its natural involution, and propranolol has been
proved to induce apoptosis of such hemangioma cells. As
suggested, apoptosis may not be complete in all cases after
treatment withdrawal, and thus some endothelial cells may
remain proliferative after treatment is stopped [9]. It is
unknown why other IH, showing only partial response to
propranolol, do not experience further proliferation of the
remaining endothelial cells after propranolol withdrawal.
The exact mechanism underlying late proliferation of
endothelial cells remains unknown. VEGF expression is
clearly involved in the proliferative phase of hemangiomas.
Lamy demonstrated that propranolol inhibited endothelial
proliferation not only through beta-adrenergic receptors, but
also by antagonizing the VEGF receptors. Thus, it might be
hypothesized that this receptor plays an important role in the
recurrence of hemangiomas after propranolol because of the
cessation of this inhibitory effect [29].
In conclusion, propranolol has a well-documented safety
and mild side effect for infantile hemangiomas. However,
propranolol for hemangiomas is an off-label-indication and
the parents have to be well informed and to assent.
Although we observed a recurrence rate of 6 % of cases of
IH treated with propranolol after withdrawal. In all, pro-
pranolol appears to be an effective treatment for infantile
hamangiomas and should now be used as a first-line treat-
ment in hemangiomas when intervention is required. Also,
further studies should be needed in determining the most
effective treatment dosage, optimum treatment duration,
and exact mechanism of action of propranolol in future.
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